Results 271 to 276 of about 46,788 (276)
Some of the next articles are maybe not open access.
Leukemia & Lymphoma, 2006
The anti-CD20 monoclonal antibody, rituximab, and interferon alpha (IFN) are active agents in advanced stage, indolent lymphoma. Some data obtained in vitro suggest upregulation of CD20 by IFN, and clinical trials have reported additive or synergistic activity of IFN with rituximab.
Peter Maslak +6 more
openaire +3 more sources
The anti-CD20 monoclonal antibody, rituximab, and interferon alpha (IFN) are active agents in advanced stage, indolent lymphoma. Some data obtained in vitro suggest upregulation of CD20 by IFN, and clinical trials have reported additive or synergistic activity of IFN with rituximab.
Peter Maslak +6 more
openaire +3 more sources
Neoplastic Epithelial Cells in a Subset of Human Thymomas Express the B Cell-Associated CD20 Antigen
The American Journal of Surgical Pathology, 1992A series of 36 human thymomas have been immunohistochemically analyzed using a panel of antibodies recognizing B-cell markers including CD20. Most thymomas exhibiting the cortical pattern, according to the criteria of Marino and Muller-Hermelink, were characterized by areas of medullary differentiation containing variable numbers of CD20+ B lymphocytes,
Facchetti Fabio +9 more
openaire +5 more sources
Abstract IA12: Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy
Cancer Immunology Research, 2017Abstract T cells expressing chimeric antigen receptors (CARs) specific for the B-cell marker CD19 have shown impressive results in the treatment of B-cell malignancies. However, multiple clinical trials have also demonstrated the vulnerability of single-input CD19 CAR-T cell therapy to antigen escape, in which patients relapse with the ...
Meng-Yin Lin +4 more
openaire +2 more sources
Leukemia Research, 2000
Anti-CD20 antibody is an established treatment for low-grade non-Hodgkin's lymphoma (NHL). Augmenting the expression of CD20 antigen on the tumor cells may increase the cell kill and therefore increase the effectiveness of the antibody. To study this, we incubated peripheral blood lymphocytes from CLL patients with the following cytokines: EPO, SCF ...
Stephanie A. Gregory +5 more
openaire +3 more sources
Anti-CD20 antibody is an established treatment for low-grade non-Hodgkin's lymphoma (NHL). Augmenting the expression of CD20 antigen on the tumor cells may increase the cell kill and therefore increase the effectiveness of the antibody. To study this, we incubated peripheral blood lymphocytes from CLL patients with the following cytokines: EPO, SCF ...
Stephanie A. Gregory +5 more
openaire +3 more sources